03 Nov 2025 | 3 Mins Read
Strides Pharma hits all-time high, sees potential for re-rating
Flipitmoney
Strides Pharma Ltd's shares surged 10% to a record high of ₹1,025, extending gains for the fourth consecutive session. The stock has rallied 26% in four trading days, with trading volumes spiking. Brokerage firm DAM Capital maintained its 'Buy' rating, expecting revenue CAGR of 12% and EBITDA CAGR of 17% between FY25 and FY27.